An observational prospective cohort study was conducted to investigate the impact of Ketamine and Lidocaine on pain alleviation in people with fibromyalgia and neuropathic non-cancer pain, and on their quality of life, anxiety, and depression.
In people with neuropathic pain and fibromyalgia, simultaneous intravenous infusion of Ketamine along with Lidocaine enhances quality of life and effectively controls chronic pain.
An observational prospective cohort study was conducted to investigate the impact of Ketamine and Lidocaine on pain alleviation in people with fibromyalgia and neuropathic non-cancer pain, and on their quality of life, anxiety, and depression.
In total, 156 individuals with neuropathic pain and/or fibromyalgia volunteered to take part. Seven common questionnaires were employed. The participants intended to get a total of 6 infusions during the 36-week research. Both before and after completing the baseline surveys, subjects were evaluated.
Every eight weeks, the infusions were planned. Before beginning the therapy, patients filled out questionnaires and rated their level of pain for each week of infusion. Using the PQAS-R questionnaire, the alteration in pain score between baseline to week 36 of the research (key endpoint) was analyzed.
In chronic neuropathic pain patients refractory to conventional drug therapy (oral medications), or when the obtained relief was insufficient, or elicited numerous side effects, the simultaneous use of Ketamine and Lidocaine was a safe and efficient intervention.
Ambulatory infusions of Lidocaine and Ketamine are effective and safe for the management of neuropathic pain and fibromyalgia.
Journal of Anesthesiology and Pain Research
Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: An Observational Prospective Cohort Study
Ramin Safakish et al.
Comments (0)